Xellsmart key facts
as of Oct 2026- Developer of stem cell treatment solutions intended to improve major disease treatment and drug discovery.
- Xellsmart is valued at approximately $158.0M as of Oct 2026 (last reported valuation).
- It has raised $156.1M; the latest was Later Stage VC ($72.4M) in Mar 2026.
- Notable investors include Suzhou Oriza Holdings Corporation, HSG (Hong Kong), Qiming Venture Partners, YuanBio Venture Capital, Frees Fund — 34 tracked in total.
- Status: Privately Held (backing).
Xellsmart's last reported valuation, Mar 2023. Nothing priced has surfaced since.
- ·The complete investor list: 34 names
- ·Watch Xellsmart: the Monday email on marks, rounds and moves
Xellsmart funding rounds
No funding rounds for Xellsmart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Xellsmart
34+Xellsmart valuation
Xellsmart's last reported valuation was $158 million in Mar 2023. No priced round, secondary trade or fund mark has surfaced since.
Xellsmart investors
34 investors are on record for Xellsmart, including Suzhou Oriza Holdings Corporation, HSG (Hong Kong), Qiming Venture Partners and YuanBio Venture Capital.
About Xellsmart
Developer of stem cell treatment solutions intended to improve major disease treatment and drug discovery. The company offers off-the-shelf candidates manufactured to clinical grade with integrated quality control, standardized processes spanning reprogramming and directed differentiation, and regulatory clearances for early-stage studies in Parkinson's disease, spinal cord injury, and amyotrophic lateral sclerosis, providing patients with clinical solutions.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Employees
- 100
- Website
- xellsmart.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.